Saturday 17 October 2026
Export SLS’s income statement to Excel — free account
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million. In the quarter to June 2026, EPS grew 28.6% and free cash flow fell 3.52%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
9.98
1.36
−11.99%
Follow SLS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(84.33%) | (66.88%) | (43.58%) | (39.63%) | |
| (66.47%) | (54.95%) | (39.50%) | (36.54%) | ||
ROIC |
(1,391.37%) | 0.00% | (9,146.22%) | 0.00% | |
Return on Tangible Assets |
(60.15%) | (39.39%) | (28.13%) | (24.06%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.28) | (0.26) | (0.16) | (0.15) | |
Free Cash Flow |
(30.62) | (28.39) | (28.16) | (28.42) | |
| Other line items | |||||
Cash ROIC |
(34.00%) | (19.89%) | (13.12%) | (10.29%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.18 | 1.06 | 0.96 | 0.88 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.28) | (0.26) | (0.16) | (0.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates